Featured Content

Conflicts of interest and the clinical investigator

Tuesday, August 1, 2017

A conflict of interest (COI) can erode the judgment of clinical research professionals, leading to questions about their professionalism and integrity. Every professional has a COI. It could be an interest in a promotion, a financial collaboration, or a need to gain more research funding or be published in a medical journal. The May 2, 2017, issue of the Journal of the American Medical Association (JAMA) looked at the issue of COI; one topic addressed biomedical researchers and the difference between financial and nonfinancial possible biases.

[Read More]

The importance of disclosure for publication

Tuesday, August 1, 2017

As clinical trial researchers seek to improve human health through their biomedical discoveries, medical journals seek to provide information and data about these discoveries in an objective and credible way. Conflict of interest (COI) issues can undermine the trust of this information, JAMA authors say in the May 2, 2017, issue primarily dedicated to the issue of COI. “[I]t is more important than ever that editors and publishers of medical journals work intelligently, and together, to redefine their policies about conflict of interest issues and to reaffirm their values focused on public trust for the integrity and independence of the editorial process,” says Thomas J. Easley, senior vice president and publisher of the JAMA Network.

[Read More]

Embrace payment technology to improve processes

Tuesday, August 1, 2017

In today’s technology-enabled world, consumers expect instant gratification, especially when it comes to payments. The clinical trial industry, which historically has been slow to embrace new technologies, must recognize that it needs to adopt new payment technologies to continue to attract patients for clinical trials. The benefits that payment automation solutions can deliver to trials, such as increased patient retention rates and enhanced patient engagement, as well as streamlined internal processes, have never been more important.

[Read More]

Crohn’s & Colitis Foundation launch Clinical Trials Community

Monday, July 31, 2017

On July 20, 2017, the Crohn’s & Colitis Foundation launched a Clinical Trials Community (the Community) for the education of patients, family members, caregivers and healthcare providers regarding the study of irritable bowel disease (IBD). Specifically, the community will provide education on the clinical trial process as well as its value for facilitating improvements in care. Subsequently, this process may help reduce barriers to patient enrollment in IBD clinical trials, thereby enabling faster routes to therapeutic discovery.

[Read More]

Three Questions: John Moore, Trialogics

Monday, July 24, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with John Moore, formerly a venture capitalist in the technology space, now executive chairman of Trialogics, a provider of clinical trial software serving biotech and pharma partners.

[Read More]

Partnership unveils EHR-EDC integration

Monday, July 24, 2017

Two industry innovators have joined forces to take the lead in real-world studies. Clinerion and Cisiv have formed a groundbreaking partnership to offer a revolutionary approach to observational research by enabling automated data transfer from electronic hospital records (EHRs) to electronic data capture (EDC).

[Read More]

Mayo Clinic and nference form Qrativ, AI platform for developing rare disease therapies

Monday, July 24, 2017

The Mayo Clinic and nference, a healthcare data synthesis company powered by artificial intelligence (AI), recently announced they’re joining forces to form the startup company Qrativ. This startup will combine nference’s AI knowledge synthesis platform and the Mayo Clinic’s experience and expertise in medicine and healthcare to identify and develop new therapies for patients where an unmet need exists. Orphan diseases have been chosen as the prime focus of Qrativ’s efforts.

[Read More]

Innovation Initiative to modernize the FDA

Monday, July 17, 2017

New FDA Commissioner Scott Gottlieb intends to release a far-reaching plan aimed at modernizing regulatory processes and speeding approvals for new drugs and devices, which could allow greater patient access to new medicines through unprecedented scientific and technological advancements.

[Read More]